Pharma BD Deal Intelligence
Pfizer's $1.3B HDL bet collapsed with torcetrapib's fatal Phase III failure; Esperion was sold back for near-nothing in 2008.
Full analysis, sources & comparables →Pfizer agreed to acquire Esperion for $1.3B at $35/share - 54% premium. Mark Monane (Needham & Co.) said 'this acquisition fits Pfizer like a glove' citing…
Pfizer discontinued all Esperion drugs after torcetrapib's late-2006 failure caused exit from cardiovascular development. Newton repurchased rights to relaunch…
Source summaries from our enrichment pipeline; follow links for originals.
All 4 sources with sentiment breakdown →
Pfizer agreed to acquire Esperion Therapeutics for ~$1.3B ($35/share, a 54% premium) to add the HDL/cardiovascular asset ETC-216; announced Dec 21, 2003 and closed Feb 10, 2004.
Pfizer's $1.3B HDL bet collapsed with torcetrapib's fatal Phase III failure; Esperion was sold back for near-nothing in 2008.
Assessment window: 15yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Pfizer Inc. / Esperion Therapeutics Inc. (this deal) | 2003 | $1.3B | 12 |
| Pfizer Inc. / BioNTech SE | 2020 | $748M | 100 |
| Pfizer Inc. / FoldRx Pharmaceuticals | 2010 | — | 99 |
| Pfizer Inc. / Medivation Inc. | 2016 | $14.0B | 86 |
| Pfizer Inc. / Wyeth | 2009 | $68.0B | 86 |
| Pfizer Inc. / Warner-Lambert Company | 2000 | $90.0B | 83 |
| Pfizer Inc. / Arvinas, Inc. | 2021 | $2.4B | 77 |
← Browse all deals · How we score deals
More: 2003 deals · Pfizer Inc. deals